Echo IQ Deploys AI Into No. 2 Ranked US Heart Hospital to Boost Valve Detection
Echo IQ deploys EchoSolv AS into top-ranked US heart hospital
AI medical technology firm Echo IQ (ASX: EIQ) has deployed its AI-based decision support software, EchoSolv AS, into Mount Sinai Health System in New York, one of America’s largest and highest-ranked cardiovascular institutions. Mount Sinai Fuster Heart Hospital is ranked No. 1 in New York and No. 2 nationally for Cardiology, Heart & Vascular Surgery in U.S. News & World Report’s 2025–26 Best Hospitals rankings.
The deployment marks a significant milestone in EIQ’s US commercial strategy, which targets leading hospital systems as reference sites to drive broader adoption. Mount Sinai Health System comprises seven hospitals, more than 400 outpatient practices, and over 3,760 beds across campuses, servicing millions of patient interactions annually.
The system is home to the Icahn School of Medicine at Mount Sinai, a globally recognised research institution, and is consistently ranked among the top US hospitals across multiple specialties. Its scale, research pedigree, and clinical leadership position it as a high-volume, high-complexity healthcare network at the forefront of adopting advanced digital health and AI-enabled technologies.
For Echo IQ, the engagement represents more than a single deployment. It provides commercial validation from a top-tier institution, creates a high-profile reference site for prospective customers, and opens potential future research collaboration opportunities as the company pursues new product development.
When big ASX news breaks, our subscribers know first
What is aortic stenosis and why does it matter?
Aortic stenosis is a condition where the heart’s aortic valve narrows, restricting blood flow from the heart to the rest of the body. Severe aortic stenosis is often under-diagnosed, meaning patients may remain untreated and unable to benefit from therapeutic advancements in aortic valve disease.
EchoSolv AS provides AI-enabled decision support during echocardiography, which is an ultrasound examination of the heart. The software offers physicians a measurement-based second look to help identify patients with severe aortic stenosis who may otherwise be missed during routine scans.
The technology is designed as an adjunct tool for interpreting physicians, not a replacement for clinical judgement. When used during echocardiography, it provides information to facilitate accurate diagnosis and support clinical review. It is intended for qualified healthcare professionals only.
The unmet clinical need for improved detection creates a clear market opportunity. AI tools that integrate into existing clinical workflows address a genuine gap in cardiovascular diagnostics, particularly in high-volume hospital systems where consistency in assessment is critical.
Inside Mount Sinai Health System
Mount Sinai Health System is a leading US healthcare network recognised for clinical excellence and innovation in cardiovascular care. The system’s scale and reputation make it a significant deployment partner for Echo IQ, both commercially and strategically.
| Metric | Detail |
|---|---|
| Hospitals | 7 |
| Outpatient practices | 400+ |
| Beds | 3,760+ |
| Cardiology ranking (NYC) | No. 1 |
| National cardiology ranking | No. 2 |
Mount Sinai’s leadership in adopting digital health and AI-enabled technologies reflects its position as an institution that sets the standard for clinical innovation. The deployment into Mount Sinai provides Echo IQ with a high-profile reference site that may accelerate conversations with other US health systems.
The system’s globally recognised Icahn School of Medicine at Mount Sinai also creates potential opportunities for future research collaboration as Echo IQ continues to develop its product suite. Partnering with a top-tier academic medical centre builds credibility and positions the company to demonstrate clinical utility at scale.
The next major ASX story will hit our subscribers first
Management commentary on US commercial momentum
US President and General Manager Nick Lubbers framed the Mount Sinai deployment as a reflection of Echo IQ’s broader growth trajectory in the US market. He emphasised that the engagement represents more than a single large-scale deployment, highlighting the company’s strategy of building partnerships with leading hospitals and expanding access to AI-enabled decision support in cardiology.
Nick Lubbers, US President and General Manager
“Mount Sinai is the kind of institution that helps set the standard for clinical excellence and innovation. For Echo IQ, this engagement represents more than a single large-scale deployment. It reflects our broader growth trajectory as we continue building partnerships with leading hospitals and expanding access to AI-enabled decision support in cardiology.”
Dr Stamatios Lerakis, Director of the Cardiovascular Imaging Program and Imaging for Structural and Valve Interventions at Mount Sinai Health System, commented on the clinical utility of EchoSolv AS. Dr Lerakis serves as a paid key opinion leader, speaker, and advisory board member for Echo IQ.
Dr Stamatios Lerakis, Director of the Cardiovascular Imaging Program and Imaging for Structural and Valve Interventions, Mount Sinai Health System
“This product can highlight patients with aortic stenosis that can be otherwise under-diagnosed, remain untreated and as a result, not benefit from the tremendous therapeutic advancements in the space of aortic valve diseases.”
Dr Lerakis positioned EchoSolv AS as an adjunct for echocardiographers, noting that the interpreting physician will always have the final say on interpretation. He described the product as strengthening patient care by supporting more consistent assessment of aortic stenosis during routine echocardiography.
What’s next for EchoSolv AS in the US
Echo IQ continues to engage with prospective US hospitals regarding potential EchoSolv AS opportunities. The company’s stated strategy centres on expanding adoption at prominent cardiovascular institutions, leveraging deployments such as Mount Sinai as reference sites to demonstrate clinical utility and scalability.
The pipeline of hospital discussions suggests further US deployment announcements may follow. Mount Sinai serves as validation for prospective customers, particularly health systems evaluating AI-enabled decision support tools for integration into existing clinical workflows.
Near-term priorities for the company include:
- Continue commercial discussions with prospective US healthcare providers
- Leverage Mount Sinai deployment as a reference site for ongoing hospital engagement
- Explore future research collaboration opportunities with Mount Sinai to support product development
The company stated it will provide updates on US commercial progress as appropriate.
Want the Next Healthcare Breakout in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX healthcare news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to get real-time alerts the moment market-moving announcements hit the ASX.